Table 3.

Risk of outcomes among cervical cancer patients with hydronephrosis stratified by developed timing after cervical cancer diagnosed.

Developed timing	Event	PY	IR	Crude HR (95% CI)	Adjusted HR (95% CI)
All-cause mortality (n = 79)
<1 week	17	740	22.97	0.59 (0.34–1.03)	0.76 (0.39–1.51)
1 week–6 month	12	399	30.08	0.72 (0.38–1.37)	0.82 (0.43–1.56)
>6 month	50	1045	47.85	1 (reference)	1 (reference)
Urethral catheter (n = 72)
<1 week	17	681	24.96	0.70 (0.40–1.24)	0.84 (0.41–1.73)
1 week–6 month	12	366	32.79	0.85 (0.44–1.63)	1.01 (0.52–1.94)
>6 month	43	1021	42.12	1 (reference)	1 (reference)
CKD (n = 125)
<1 week	33	610	54.10	0.80 (0.53–1.21)	1.08 (0.61–1.92)
1 week–6 month	14	373	37.53	0.52 (0.29–0.92)	0.68 (0.37–1.26)
>6 month	78	886	88.04	1 (reference)	1 (reference)
Removal of DJ (n = 70)
<1 week	25	622	40.19	2.33 (1.40–3.88)∗∗	2.14 (1.08–4.22)
1 week–6 month	8	353	22.66	0.69 (0.32–1.49)	0.82 (0.37–1.82)
>6 month	37	944	39.19	1 (reference)	1 (reference)
PCN (n = 102)
<1 week	24	680	35.29	0.57 (0.34–0.94)∗	0.69 (0.35–1.36)
1 week–6 month	19	325	58.46	0.80 (0.47–1.34)	0.82 (0.48–1.40)
>6 month	59	921	64.06	1 (reference)	1 (reference)
Keep DJ (n = 133)
<1 week	26	610	42.62	1.17 (0.75–1.84)	1.20 (0.66–2.17)
1 week–6 month	32	228	140.35	1.04 (0.68–1.57)	1.14 (0.75–1.76)
>6 month	75	804	93.28	1 (reference)	1 (reference)
Infection (n = 116)
<1 week	39	493	79.11	1.52 (1.01–2.30)∗	1.16 (0.66–2.06)
1 week–6 month	21	274	76.64	1.26 (0.76–2.09)	1.26 (0.75–2.11)
>6 month	56	800	70.00	1 (reference)	1 (reference)
Urinary stones (n = 95)
<1 week	27	551	49.00	0.95 (0.60–1.51)	1.10 (0.59–2.07)
1 week–6 month	11	344	31.98	0.76 (0.93–1.46)	0.74 (0.38–1.45)
>6 month	57	774	73.64	1 (reference)	1 (reference)

HR adjusted for age, gender, diabetes mellitus, hypertension, chronic kidney disease (CKD) and cancer.

CI = confidence interval, HR = hazard ratio, IR = incidence rate, per 1000 person-years, PCN = percutaneous nephrostomy, PY = person-years.

^∗P < .05.

^∗∗P < .01.

^∗∗∗P < .001.